HIV pill genvoya tested in teens and kids – could simplify treatment
NCT ID NCT01854775
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the HIV medication Genvoya (a single daily pill) in 129 teenagers and children with HIV. The goal was to check how the drug is processed in the body, confirm the right dose, and see if it is safe. Participants included teens new to HIV treatment and children who already had the virus under control. The results help doctors know how to use this medicine in younger patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide)
What this could lead to
If successful, this study helps confirm that Genvoya is safe and works well for treating HIV in teenagers and children, offering a simpler once-daily pill option.
What could go wrong
This is an early-to-mid stage study with a small number of participants (129). It focuses on dosing and short-term safety, not long-term outcomes. Side effects or lack of effectiveness in younger children are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Be Part Yoluntu Centre
Cape Town, 7646, South Africa
-
Children's Research Institute
Washington D.C., District of Columbia, 20010, United States
-
Clinical HIV Research Unit
Johannesburg, 2041, South Africa
-
Department of Pediatrics, Faculty of Medicine, Khon Kaen University
Khon Kaen, 40002, Thailand
-
Desmond Tutu HIV Foundation
Cape Town, 7705, South Africa
-
Emory University School of Medicine
Atlanta, Georgia, 30322, United States
-
Empilweni Services and Research Unit (ESRU)
Johannesburg, 2092, South Africa
-
Joint Clinical Research Centre
Kampala, PO Box 10005, Uganda
-
KIDCRU Ward J8
Cape Town, 7505, South Africa
-
Miller's Children Hospital
Long Beach, California, 90806, United States
-
Perinatal HIV Research Unit Baragwanath Hospital
Johannesburg, 1862, South Africa
-
Queen Savang Vadhana Memorial Hospital
Chon Buri, 20110, Thailand
-
Seattle Children's Hospital
Seattle, Washington, 98105-0371, United States
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
-
The HIV Netherlands Australia Thailand Research collaboration (HIV-NAT)
Bangkok, 10330, Thailand
-
University of Zimbabwe - Clinical Research Centre
Belgravia, 263, Zimbabwe